Mahboobeh Nazari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mahboobeh Nazari has a total of 87 co-authors. Here are the top co-authors by number of shared publications:
- Rahman Emamzadeh
Department of Cell and Molecular Biology and Microbiology, Faculty of Biological Science and Technology, University of Isfahan, Isfahan, Iran
6 shared publications Rahman Emamzadeh
Department of Cell and Molecular Biology and Microbiology, Faculty of Biological Science and Technology University of Isfahan Isfahan Iran
4 shared publicationsArash Minai-Tehrani
Nanobiotechnology Research Center , ACECR , Avicenna Research Institute , Tehran , Iran , avicenna.ac.ir
3 shared publicationsMaryam Mehravar
Reproductive Biotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran
3 shared publicationsRoya Ghods
Department of Molecular Medicine, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran
3 shared publicationsSaeideh Zamani Koukhaloo
Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran
3 shared publications
Latest Publications
- Open Access
- 27 September 2026
- Published by Elsevier in Veterinary and Animal Science
- Vol. 34, 100883
Advances and challenges in avian influenza vaccines: From conventional approaches to next-generation strategies
- 27 September 2026
- Published by Elsevier in Veterinary and Animal Science
- Vol. 34, 100883
Open AccessAdvances and challenges in avian influenza vaccines: From conventional approaches to next-generation strategies
- Open Access
- 6 August 2026
- Published by Wiley in Analytical Science Advances
- Vol. 7 (2) , e70104
Lipopolysaccharide‐Specific Aptasensor: A Spectroscopic Approach for Identifying Gram‐Negative Bacteria
Differentiating bacteria into Gram‐negative and Gram‐positive categories is a standard method of identification in biological science and is essential for understanding bacterial characteristics. This study presents a novel aptasensor that integrates an anti‐lipopolysaccharide (LPS) aptamer with a G‐quadruplex‐based DNAzyme. This aptasensor enables spectroscopy‐based detection of LPS‐containing Gram‐negative bacteria. With a detection limit of approximately 2.7 × 10 5 cells/mL for Escherichia coli , this aptasensor offers an efficient and straightforward solution for laboratory detection of Gram‐negative bacteria.
- 6 August 2026
- Published by Wiley in Analytical Science Advances
- Vol. 7 (2) , e70104
Open AccessLipopolysaccharide‐Specific Aptasensor: A Spectroscopic Approach for Identifying Gram‐Negative Bacteria
Differentiating bacteria into Gram‐negative and Gram‐positive categories is a standard method of identification in biological science and is essential for understanding bacterial characteristics. This study presents a novel aptasensor that integrates an anti‐lipopolysaccharide (LPS) aptamer with a G‐quadruplex‐based DNAzyme. This aptasensor enables spectroscopy‐based detection of LPS‐containing Gram‐negative bacteria. With a detection limit of approximately 2.7 × 10 5 cells/mL for Escherichia coli , this aptasensor offers an efficient and straightforward solution for laboratory detection of Gram‐negative bacteria.
- Open Access
- 28 February 2026
- Published by Elsevier in Comparative Immunology Reports
- Vol. 10
Oral vaccines for rainbow trout: Promising solutions to combat bacterial and viral pathogens in aquaculture
- 28 February 2026
- Published by Elsevier in Comparative Immunology Reports
- Vol. 10
Open AccessOral vaccines for rainbow trout: Promising solutions to combat bacterial and viral pathogens in aquaculture
- Open Access
- 17 February 2026
- Published by Knowledge E DMCC in Avicenna Journal of Medical Biotechnology
- Vol. 18 (1) , 55-60
Expression, Purification, and Application of SARS-CoV-2 Nucleocapsid Protein for Serological Detection of IgG and IgM Antibodies
Background: SARS-CoV-2 is a novel coronavirus that has caused dramatic loss of life and poses an unprecedented public health challenge worldwide. The nucleocapsid (N) protein of SARS-CoV-2 is the most abundant viral protein and a potent immunogen. Methods: In the current study, the N gene of SARS-CoV-2 was amplified from RNA extracted from a COVID-19 positive patient and then cloned into the pCold-I expression vector. The full-length His-tagged N protein was expressed in Escherichia coli (E. coli) using 0.5 mM IPTG and subsequently purified by nickel affinity chromatography. The purified N protein was characterized using sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) and Western blotting. Furthermore, the purified N protein was applied in SARS-CoV-2 IgG and IgM ELISA immunoassays. Results: The results showed that purification of the N protein in the presence of urea yielded a protein band of approximately 48 kDa on SDS-PAGE, corresponding to the full-length N protein. Additionally, Western blot analysis of the purified recombinant N protein showed a band of the same molecular weight. In the SARS-CoV-2 IgG ELISA assay, anti-N protein antibodies from a COVID-19 positive patient’s serum successfully recognized the coated N protein. In the IgM ELISA test, an N-HRP conjugate was used in ELISA wells to reveal the interaction of HRP-conjugated N protein with pre-coated anti-N protein antibodies (IgM isotype). Conclusion: These results indicate that the expressed N protein of SARS-CoV-2 could serve as a valuable reagent for the development of antibody-based immunoassays to detect SARS-CoV-2 IgG and IgM antibodies.
- 17 February 2026
- Published by Knowledge E DMCC in Avicenna Journal of Medical Biotechnology
- Vol. 18 (1) , 55-60
Open AccessExpression, Purification, and Application of SARS-CoV-2 Nucleocapsid Protein for Serological Detection of IgG and IgM Antibodies
Background: SARS-CoV-2 is a novel coronavirus that has caused dramatic loss of life and poses an unprecedented public health challenge worldwide. The nucleocapsid (N) protein of SARS-CoV-2 is the most abundant viral protein and a potent immunogen. Methods: In the current study, the N gene of SARS-CoV-2 was amplified from RNA extracted from a COVID-19 positive patient and then cloned into the pCold-I expression vector. The full-length His-tagged N protein was expressed in Escherichia coli (E. coli) using 0.5 mM IPTG and subsequently purified by nickel affinity chromatography. The purified N protein was characterized using sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) and Western blotting. Furthermore, the purified N protein was applied in SARS-CoV-2 IgG and IgM ELISA immunoassays. Results: The results showed that purification of the N protein in the presence of urea yielded a protein band of approximately 48 kDa on SDS-PAGE, corresponding to the full-length N protein. Additionally, Western blot analysis of the purified recombinant N protein showed a band of the same molecular weight. In the SARS-CoV-2 IgG ELISA assay, anti-N protein antibodies from a COVID-19 positive patient’s serum successfully recognized the coated N protein. In the IgM ELISA test, an N-HRP conjugate was used in ELISA wells to reveal the interaction of HRP-conjugated N protein with pre-coated anti-N protein antibodies (IgM isotype). Conclusion: These results indicate that the expressed N protein of SARS-CoV-2 could serve as a valuable reagent for the development of antibody-based immunoassays to detect SARS-CoV-2 IgG and IgM antibodies.
- Open Access
- 17 February 2026
- Published by Knowledge E DMCC in Avicenna Journal of Medical Biotechnology
- Vol. 18 (1) , 39-47
Step-by-Step Preparation of Immobilized Recombinant Staphylococcus aureus Protein A (SpA): A Versatile Tool for Efficient Antibody Purification
Background: This study highlights the significance of using Staphylococcus aureus (S. aureus) Protein A (SpA) for antibody purification. Methods: The gene encoding Protein A was isolated from S. aureus and cloned into the pET-28a vector. Following transformation into Escherichia coli (E. coli) BL21, recombinant Protein A was expressed and purified using a nickel affinity resin. Results: The recombinant expression of protein A produced a yield of 50 mg/L, indicating a substantial production efficiency. The characterization of the recombinant protein through various ELISA tests confirmed its binding affinity to antibodies. Subsequently, the recombinant Protein A was immobilized on two different matrices: activated Sepharose 4B and amine-functionalized magnetic nanoparticles. Conclusion: The immobilization on magnetic nanoparticles presents a versatile alternative, offering the advantages of rapid separation, high surface area, and ease of handling. Magnetic nanoparticles facilitate automation and reduce processing time, making them particularly attractive for clinical and industrial applications. These immobilized forms were used to efficiently purify serum IgG, demonstrating the potential of Protein A as an effective tool for antibody isolation in biotechnological applications
- 17 February 2026
- Published by Knowledge E DMCC in Avicenna Journal of Medical Biotechnology
- Vol. 18 (1) , 39-47
Open AccessStep-by-Step Preparation of Immobilized Recombinant Staphylococcus aureus Protein A (SpA): A Versatile Tool for Efficient Antibody Purification
Background: This study highlights the significance of using Staphylococcus aureus (S. aureus) Protein A (SpA) for antibody purification. Methods: The gene encoding Protein A was isolated from S. aureus and cloned into the pET-28a vector. Following transformation into Escherichia coli (E. coli) BL21, recombinant Protein A was expressed and purified using a nickel affinity resin. Results: The recombinant expression of protein A produced a yield of 50 mg/L, indicating a substantial production efficiency. The characterization of the recombinant protein through various ELISA tests confirmed its binding affinity to antibodies. Subsequently, the recombinant Protein A was immobilized on two different matrices: activated Sepharose 4B and amine-functionalized magnetic nanoparticles. Conclusion: The immobilization on magnetic nanoparticles presents a versatile alternative, offering the advantages of rapid separation, high surface area, and ease of handling. Magnetic nanoparticles facilitate automation and reduce processing time, making them particularly attractive for clinical and industrial applications. These immobilized forms were used to efficiently purify serum IgG, demonstrating the potential of Protein A as an effective tool for antibody isolation in biotechnological applications
- Open Access
- 1 January 2026
- Published by Institution of Engineering and Technology (IET) in IET Nanobiotechnology
- Vol. 2026 (1) , 6621537
Zn‐Conjugated Graphene Oxide Nanoparticle–Mediated Inhibition of Human Islet Amyloid Polypeptide (hIAPP) Amyloid Formation: Their Synergistic Effects
Human islet amyloid polypeptide (hIAPP) oligomers, formed through an accumulation pathway, are toxic to insulin‐secreting pancreatic β‐cells and are considered to contribute for β‐cell death and insulin deficiency commonly observed in type 2 diabetes (T2D) patients. In this study, we investigated and compared the antiaggregation effects of several nanoparticles (NPs) including zinc acetate, graphene oxide (GO), and zinc‐conjugated GO (GO–NH 2 –Zn) on their interactions with hIAPP. For this purpose, GO was purchased and subsequently conjugated with zinc acetate. Recombinant hIAPP was produced and its amyloidogenic behavior was evaluated in the presence of different concentrations of GO, zinc acetate, and GO–NH 2 –Zn. Thioflavin T (ThT) fluorescence spectroscopy was applied to examine the amyloid behavior of the protein. Additionally, the transmission electron microscopy (TEM) images of amyloid particles alone and in the presence of GO–NH 2 –Zn NP were recorded. A cell toxicity assay revealed these NPs protected insulin‐secreting NIT‐1 pancreatic β‐cells from hIAPP–induced toxicity. TEM images and ThT fluorescence spectra confirmed the reduction in hIAPP aggregation in the presence of GO–NH 2 –Zn. Our results clearly demonstrated that both zinc acetate and GO extended the lag‐phase latency to form amyloid fibrils, while GO–NH 2 –Zn exerted a synergistic inhibitory effect on fibril formation. Furthermore, when GO–NH 2 –Zn was incubated with fetal bovine serum (FBS) to form a hard corona mimicking in vivo circumstances, it effectively prevented the formation of amyloid as expected. Our study suggests that the GO–NH 2 –Zn, as an antiaggregation NP, has potential for use in designing new nanomedicine agents to inhibit hIAPP fibril formation and treat T2D disease.
- 1 January 2026
- Published by Institution of Engineering and Technology (IET) in IET Nanobiotechnology
- Vol. 2026 (1) , 6621537
Open AccessZn‐Conjugated Graphene Oxide Nanoparticle–Mediated Inhibition of Human Islet Amyloid Polypeptide (hIAPP) Amyloid Formation: Their Synergistic Effects
Human islet amyloid polypeptide (hIAPP) oligomers, formed through an accumulation pathway, are toxic to insulin‐secreting pancreatic β‐cells and are considered to contribute for β‐cell death and insulin deficiency commonly observed in type 2 diabetes (T2D) patients. In this study, we investigated and compared the antiaggregation effects of several nanoparticles (NPs) including zinc acetate, graphene oxide (GO), and zinc‐conjugated GO (GO–NH 2 –Zn) on their interactions with hIAPP. For this purpose, GO was purchased and subsequently conjugated with zinc acetate. Recombinant hIAPP was produced and its amyloidogenic behavior was evaluated in the presence of different concentrations of GO, zinc acetate, and GO–NH 2 –Zn. Thioflavin T (ThT) fluorescence spectroscopy was applied to examine the amyloid behavior of the protein. Additionally, the transmission electron microscopy (TEM) images of amyloid particles alone and in the presence of GO–NH 2 –Zn NP were recorded. A cell toxicity assay revealed these NPs protected insulin‐secreting NIT‐1 pancreatic β‐cells from hIAPP–induced toxicity. TEM images and ThT fluorescence spectra confirmed the reduction in hIAPP aggregation in the presence of GO–NH 2 –Zn. Our results clearly demonstrated that both zinc acetate and GO extended the lag‐phase latency to form amyloid fibrils, while GO–NH 2 –Zn exerted a synergistic inhibitory effect on fibril formation. Furthermore, when GO–NH 2 –Zn was incubated with fetal bovine serum (FBS) to form a hard corona mimicking in vivo circumstances, it effectively prevented the formation of amyloid as expected. Our study suggests that the GO–NH 2 –Zn, as an antiaggregation NP, has potential for use in designing new nanomedicine agents to inhibit hIAPP fibril formation and treat T2D disease.
- 2 June 2025
- Published by Springer Nature in Medical Oncology
- Vol. 42 (7) , 1-14
Targeting endothelial growth factor receptor in thyroid cancer: current concepts and future directions
Thyroid cancer (TC) ranks among the most prevalent cancers globally. The incidence rate of thyroid cancer has significantly risen in the past few decades. Most patients with differentiated thyroid cancer can be effectively treated with thyroidectomy and radioiodine adjuvant therapy. However, the management of locally advanced or distant metastatic TC remains challenging, especially in radioactive iodine-resistant tumors. Targeted therapy is the use of drugs designed to target overexpressed molecules in cancer cells. Epidermal growth factor receptor (EGFR) is a cell surface protein that plays a crucial role in cell proliferation, differentiation, and migration. Several studies have indicated that EGFR is overexpressed in thyroid cancer, making it a promising target in cancer treatment. In this review, we aimed to provide the functional significance of EGFR signaling pathway in TC. In addition, current strategies using anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors for treating thyroid cancer are explored.
- 2 June 2025
- Published by Springer Nature in Medical Oncology
- Vol. 42 (7) , 1-14
Targeting endothelial growth factor receptor in thyroid cancer: current concepts and future directions
Thyroid cancer (TC) ranks among the most prevalent cancers globally. The incidence rate of thyroid cancer has significantly risen in the past few decades. Most patients with differentiated thyroid cancer can be effectively treated with thyroidectomy and radioiodine adjuvant therapy. However, the management of locally advanced or distant metastatic TC remains challenging, especially in radioactive iodine-resistant tumors. Targeted therapy is the use of drugs designed to target overexpressed molecules in cancer cells. Epidermal growth factor receptor (EGFR) is a cell surface protein that plays a crucial role in cell proliferation, differentiation, and migration. Several studies have indicated that EGFR is overexpressed in thyroid cancer, making it a promising target in cancer treatment. In this review, we aimed to provide the functional significance of EGFR signaling pathway in TC. In addition, current strategies using anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors for treating thyroid cancer are explored.
- 10 July 2023
- Published by Royal Society of Chemistry (RSC) in Analytical Methods
- Vol. 15 (32) , 3924-3931
Tri-part NanoLuc as a new split technology with potential applications in chemical biology: a mini-review
For several decades, researchers have been using protein-fragment complementation assay (PCA) approaches for biosensing to study protein–protein interaction for a variety of aims, including viral infection, cellular apoptosis, G protein coupled receptor (GPCR) signaling, drug and substrate screening, and protein aggregation and protein editing by CRISPR/Cas9. As a reporter, NanoLuc (NLuc), a smaller and the brightest engineered luciferase derived from deep-sea shrimp Oplophorus gracilirostris, has been found to have many benefits over other luminescent enzymes in PCA. Inspired by the split green fluorescent protein (GFP) and its β-barrel structure, two split NLuc consisting of peptide fragments have been reported including the binary and ternary NLuc systems. NanoBiT® (large fragment + peptide) has been used extensively. In contrast, tripart split NLuc (large fragment + 2 peptides) has been applied and hardly used, while it has some advantages over NanoBiT in some studies. Nevertheless, tripart NLuc has some drawbacks and challenges to overcome but has several potential characteristics to become a multifunctional and powerful tool. In this review, several aspects of tripart NLuc are studied and a brief comparison with NanoBiT® is given.
- 10 July 2023
- Published by Royal Society of Chemistry (RSC) in Analytical Methods
- Vol. 15 (32) , 3924-3931
Tri-part NanoLuc as a new split technology with potential applications in chemical biology: a mini-review
For several decades, researchers have been using protein-fragment complementation assay (PCA) approaches for biosensing to study protein–protein interaction for a variety of aims, including viral infection, cellular apoptosis, G protein coupled receptor (GPCR) signaling, drug and substrate screening, and protein aggregation and protein editing by CRISPR/Cas9. As a reporter, NanoLuc (NLuc), a smaller and the brightest engineered luciferase derived from deep-sea shrimp Oplophorus gracilirostris, has been found to have many benefits over other luminescent enzymes in PCA. Inspired by the split green fluorescent protein (GFP) and its β-barrel structure, two split NLuc consisting of peptide fragments have been reported including the binary and ternary NLuc systems. NanoBiT® (large fragment + peptide) has been used extensively. In contrast, tripart split NLuc (large fragment + 2 peptides) has been applied and hardly used, while it has some advantages over NanoBiT in some studies. Nevertheless, tripart NLuc has some drawbacks and challenges to overcome but has several potential characteristics to become a multifunctional and powerful tool. In this review, several aspects of tripart NLuc are studied and a brief comparison with NanoBiT® is given.
- 14 April 2023
- Published by Elsevier in Process Biochemistry
- Vol. 130, 245-255
Structural studies and cell proliferation activity of human Follistatin-like 1 in reducing and non-reducing conditions
- 14 April 2023
- Published by Elsevier in Process Biochemistry
- Vol. 130, 245-255
Structural studies and cell proliferation activity of human Follistatin-like 1 in reducing and non-reducing conditions